Goldman Sachs Initiates Acorda Therapeutics With Neutral

Loading...
Loading...
Analysts at Goldman Sachs initiated coverage on shares of Acorda Therapeutics
ACOR
with a Neutral rating. The target price for Acorda Therapeutics is set to $40. Acorda Therapeutics shares have surged 15.26% over the past 52 weeks, while the S&P 500 index has gained 14.78% in the same period. Acorda Therapeutics' shares fell 1.19% to close at $36.40 yesterday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsGoldman Sachs
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...